Home / Stocks / OPRX

OptimizeRx (OPRX, Health Care Technology) Stock Valuation & Fair Value Quality business with a solid forward outlook

OptimizeRx (OPRX, Health Care Technology) trades at a blended P/E of 7.5, about 91% below its historical normal valuation, with a forward growth estimate of 8.6% and a PEG of 0.87. Analysts' one-year estimates have been hit 18% of the time. Priced at its historical normal P/E of 85.9 on the same blended earnings, the 2026-09-18 close of $7.29 corresponds to about $83.40 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
7.5
Normal P/E
85.9
PEG
0.87
Fwd growth
8.6%
Div yield
0.0%
RSI (14)
46.2
Neutral

The Street vs SeerForecast

Wall Street's mean price target for OPRX is $12.40 across 5 analysts, 63.2% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: quality business with a solid forward outlook. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.

Blended P/E and rating by weekBlended P/E moved from 6.9 to 7.5 between 2026-08-07 and 2026-09-21, against a normal P/E of 85.9, with 2 rating changes over 16 recorded weeks.2026-08-07: P/E 6.9, Quality business with a solid forward outlook (recalculated)2026-08-10: P/E 7.3, Quality business with a solid forward outlook2026-08-14: P/E 7.3, Quality business with a solid forward outlook (recalculated)2026-08-17: P/E 8.9, High quality, attractively priced for its growth2026-08-21: P/E 8.9, High quality, attractively priced for its growth (recalculated)2026-08-24: P/E 7.9, High quality, attractively priced for its growth2026-08-27: P/E 7.9, High quality, attractively priced for its growth (recalculated)2026-08-28: P/E 7.9, High quality, attractively priced for its growth (recalculated)2026-08-30: P/E 7.9, High quality, attractively priced for its growth (recalculated)2026-08-31: P/E 8.1, High quality, attractively priced for its growth2026-09-05: P/E 8.1, High quality, attractively priced for its growth (recalculated)2026-09-07: P/E 8.1, High quality, attractively priced for its growth2026-09-12: P/E 8.1, High quality, attractively priced for its growth (recalculated)2026-09-14: P/E 7.5, High quality, attractively priced for its growth2026-09-19: P/E 7.5, High quality, attractively priced for its growth (recalculated)2026-09-21: P/E 7.5, Quality business with a solid forward outlook20.040.060.080.0Aug 7Aug 18Aug 29Sep 10Sep 21Normal P/E 85.9
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-08-07P/E 6.9-92%Quality business with a solid forward outlook
2026-08-17P/E 8.9-90%High quality, attractively priced for its growth
2026-09-21P/E 7.5-91%Quality business with a solid forward outlook ← now

Frequently asked questions

Is OptimizeRx stock overvalued?

At a blended P/E of 7.5 versus its historical normal P/E of 85.9, OptimizeRx trades about 91% below its typical valuation, with a PEG of 0.87 on 8.6% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is OptimizeRx's fair value and PEG?

OptimizeRx trades at a blended P/E of 7.5 against a historical normal P/E of 85.9, a PEG of 0.87, and a forward growth estimate of 8.6%. Priced at its historical normal P/E of 85.9 on the same blended earnings, the 2026-09-18 close of $7.29 corresponds to about $83.40 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of OptimizeRx changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.

What is the analyst price target for OptimizeRx?

The mean Wall Street price target for OptimizeRx is $12.40 across 5 analysts, 63.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Technology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track OPRX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.